A £24m clinical research centre is to be built in Birmingham, UK, to bring pharmaceutical professionals together in order to advance development of research findings.
The new Institute for Translational Medicine will receive £12m from the UK Government’s ‘city deal’, with the University of Birmingham and University Hospitals Birmingham contributing the remaining the funds.
The aim of the centre is to progress major research findings from the University of Birmingham into treatment drugs for illnesses such as cancer and liver disease.
It is also hoped the new clinic will make it easier for SMEs and large pharmaceutical and biotech companies to collaborate closer.
In addition, it will increase capacity for clinical trials and make it simpler for patients to be see clinicians and researchers in the same facility.
Provost and vice-principal of University of Birmingham, professor Michael Sheppard, said: "This investment will further enhance our expertise in clinical trials and ensure that the University of Birmingham’s world-class medical research translates directly to enhanced treatments for patients.
"Our outstanding track record in translational medicine makes Birmingham the ideal place to locate the institute."
Investment in a clinical trial goes against the current trend of pharmaceutical companies slashing redevelopment and development budgets.
Recently Sanofi cut research and development jobs by around 2,000 and in the last year Pfizer announced significant cuts to its budget and closed down a prominent research site in Sandwich, UK.
Image: University of Birmingham Medical School. Photo: courtesy of Gavin Warrins.